Data

A single arm phase II study to individualize dasatinib dosing based on trough levels and molecular response to maintain efficacy whilst minimising toxicity (CML12)

Health Data Australia Contributor Records

Yeung, David ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)

Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]

ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/KBSH-1F21&rft.title=A single arm phase II study to individualize dasatinib dosing based on trough levels and molecular response to maintain efficacy whilst minimising toxicity (CML12)&rft.identifier=http://doi.org/10.58109/KBSH-1F21&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=Dataset includes: Data for 80 patients over 60 with newly diagnosed CML, using desatinib and monitoring lung function Diagnostic data, treatment data, outcome data Cancer Australia demographic data -Year of birth -Aboriginal or Torres Strait Islander status (or Ethnicity)&rft.creator=Yeung, David &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12616000738426&rft_subject=Cancer therapy (excl. chemotherapy and radiation therapy)&rft_subject=Molecular targets&rft.type=dataset&rft.language=English Access data via landing page

Cite Saved to MyRDA Save to MyRDA

Full description

Dataset includes: Data for 80 patients over 60 with newly diagnosed CML, using desatinib and monitoring lung function Diagnostic data, treatment data, outcome data Cancer Australia demographic data -Year of birth -Aboriginal or Torres Strait Islander status (or Ethnicity)

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph

Subjects

Cancer therapy (excl. chemotherapy and radiation therapy) | Molecular targets |

User Contributed Tags

Login to tag this record with meaningful keywords to make it easier to discover

Other Information

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

doi : https://doi.org/10.1182/blood-2019-127619 DOI Link

Australasian Leukaemia And Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers

DOI : 10.58109/KBSH-1F21